ArticleCancers2021
Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Prevalence of BRCA1/2 variants in an Ovarian Cancer Cohort: outcomes from a Nationwide Testing Program.European journal of human genetics : EJHG · 2026Article
- Awareness, uptake, and determinants of germline genetic testing in Chinese epithelial ovarian cancer patients: a cross-sectional study.Frontiers in oncology · 2026Article
- Routine Tumor Testing for Homologous Recombination Deficiency in Patients With High Grade Epithelial Ovarian Cancer at a Statewide Gynecological Cancer Service in Western Australia: An Observational Study.Cancer reports (Hoboken, N.J.) · 2025Observational
- Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.International journal of cancer · 2025Article
- Article
- Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel.Cancer research and treatment · 2025Article
- Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project.BMJ open quality · 2025Article
- The potential clinical utility of Whole Genome Sequencing for patients with cancer: evaluation of a regional implementation of the 100,000 Genomes Project.British journal of cancer · 2024Article
- Economic Evaluation of Population-Based BRCA1 and BRCA2 Testing in Canada.JAMA network open · 2024Article
- Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024Review
- Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.JAMA network open · 2024Article
- Consumer-oriented (patient and family) outcomes from nursing in genomics: a scoping review of the literature (2012-2022).Frontiers in genetics · 2024Article
- Article
- UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:Journal of medical genetics · 2023Article
- Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.Molecular genetics & genomic medicine · 2023Article
- Hereditary Women's Cancer: Management and Risk-Reducing Surgery.Medicina (Kaunas, Lithuania) · 2023Review
- Population-based genetic testing for cancer susceptibility genes: quo vadis?BJOG : an international journal of obstetrics and gynaecology · 2023Article
- Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.Cancers · 2022Review
- Laboratory Cross-Comparison and Ring Test Trial for TumorJournal of personalized medicine · 2022Article
- Germline Testing and Somatic Tumor Testing forJCO precision oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 6 institutions in 3 countries.
Dhivya ChandrasekaranWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Monika SobocanWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0003-1384-9487
Oleg BlyussSchool of Physics, Engineering and Computer Science, University of Hertfordshire, Hatfield AL10 9AB, UK.ORCID 0000-0002-0194-6389
Rowan E MillerDepartment of Medical Oncology, Barts Health NHS Trust, London EC1A 7BE, UK.
Olivia EvansWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Shanthini M CruszDepartment of Medical Oncology, Barts Health NHS Trust, London EC1A 7BE, UK.
Tina Mills-BaldockDepartment of Medical Oncology, Barking, Havering & Redbridge University Hospitals, Essex RM7 0AG, UK.ORCID 0000-0002-8787-0353
Li SunWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Rory F L HammondDepartment of Pathology, Barts Health NHS Trust, London E1 1FR, UK.
Faiza GabaWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Lucy A JenkinsNorth East Thames Regional Genetics Service, Great Ormond Street Hospital, London WC1N 3JH, UK.
Munaza AhmedNorth East Thames Regional Genetics Service, Great Ormond Street Hospital, London WC1N 3JH, UK.
Ajith KumarNorth East Thames Regional Genetics Service, Great Ormond Street Hospital, London WC1N 3JH, UK.
Arjun JeyarajahDepartment of Gynaecological Oncology, Barts Health NHS Trust, London EC1 1BB, UK.
Alexandra C LawrenceDepartment of Gynaecological Oncology, Barts Health NHS Trust, London EC1 1BB, UK.
Elly BrockbankDepartment of Gynaecological Oncology, Barts Health NHS Trust, London EC1 1BB, UK.
Saurabh PhadnisDepartment of Gynaecological Oncology, Barts Health NHS Trust, London EC1 1BB, UK.
Mary QuigleyDepartment of Medical Oncology, Barking, Havering & Redbridge University Hospitals, Essex RM7 0AG, UK.
Fatima El KhoulyDepartment of Medical Oncology, Barking, Havering & Redbridge University Hospitals, Essex RM7 0AG, UK.
Rekha WuntakalDepartment of Gynaecology, Barking, Havering & Redbridge University Hospitals, Essex RM7 0AG, UK.
Asma FaruqiDepartment of Pathology, Barts Health NHS Trust, London E1 1FR, UK.
Giorgia TrevisanDepartment of Pathology, Barts Health NHS Trust, London E1 1FR, UK.
Laura CaseyDepartment of Pathology, Barts Health NHS Trust, London E1 1FR, UK.
George J BurghelManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Helene SchlechtManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Michael BulmanManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Philip SmithManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Naomi L BowersManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Rosa LegoodDepartment of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London WC1H 9SH, UK.
Michelle LockleyBarts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Andrew WallaceManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.
Naveena SinghDepartment of Pathology, Barts Health NHS Trust, London E1 1FR, UK.
D Gareth EvansManchester Centre for Genomic Medicine, Saint Marys Hospital, Manchester M13 9WL, UK.ORCID 0000-0002-8482-5784
Ranjit ManchandaWolfson Institute of Population Health, Barts CRUK Cancer Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.ORCID 0000-0003-3381-5057
Barts Health NHS Trust · GBQueen Mary University of London · GBBarking, Havering And Redbridge University Hospitals NHS Trust · GBGreat Ormond Street Hospital · GBLondon School of Hygiene & Tropical Medicine · GBUniversity of Hertfordshire · GB
Funding
Barts Charity ECMG1B6R
Abstract
We present findings of a cancer multidisciplinary-team (MDT) coordinated mainstreaming pathway of unselected 5-panel germline
Indexed as
BRCABRIP1genetic testinggermlineovarian cancerRAD51CRAD51Dsomatic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.